SSTR2 and neoplasm: The overexpression of SSTR2 in NETs has enabled the development and FDA approval of radiolabeled somatostatin analogs, such as (68Gallium) 68Ga-DOTATATE for PET imaging and (177Lutetium) 177Lu-DOTATATE for PRRT, offering precise tumor visualization and effective targeted therapy [2,3].